Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial

September 22, 2016

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing ab interno canaloplasty with selective laser trabeculoplasty. Study will evaluate the safety and effectiveness of an ab interno procedure for patients with primary open angle glaucoma who do not have co-existing cataracts – the majority of the glaucoma patient population.

In The Media

Want to speak to one of our representatives?

Contact Us